31 results about "BK virus" patented technology

A method for using thiazine dyes, especially methylene blue or methylene blue derivatives, in an immediate or controlled release formulation, alone or in combination with low levels of light or other drugs, to selectively inactivate or inhibit hepatitis infection, has been developed. Clinical trial results demonstrate efficacy in a human clinical trial for treatment of hepatitis C by oral administration of methylene blue immediate release formulation, in a dosage of 65 mg twice daily, over a period of at least 100 days. A method for using thiazine dyes, especially methylene blue or methylene blue derivatives, in an immediate or controlled release formulation, along or in combination with low levels of light or other drugs, to prevent or decrease reactivation of viruses, is also described. The preferred class of patient is infected with, or has been exposed to, viruses such as Herpes simplex virus type 1 & 2, Varicella zoster virus, Epstein-Barr virus, Cytomegalovirus, and Herpes virus type 6 & 7, Adenovirus, and Human polyoma viruses, e.g. JC virus and BK virus. In one embodiment the thiazine dye is administered to a patient experiencing symptoms or disease caused by reactivation of a virus. In a preferred embodiment the thiazine dye is administered to a patient at risk for or experiencing symptoms or disease caused by reactivation of a virus, prior to or during immunosuppression or chemotherapy.

The present invention relates to HLA-A*02-restricted cellular epitopes within the VP1 polypeptide of a human polyomavirus, BK virus, which is associated with polyomavirus-associated nephropathy in kidney transplant patients. Preferred peptides correspond to amino acids residues 107-116, 108-116 and 44-52 of BKV VP1, and are processed in vivo in natural infection with BKV. Effector T cell populations stimulated by the peptides represent functional CTLs as assessed by cytotoxicity and cytokine production, and are reactive against cells presenting both the BKV peptides above and the JC virus homolog sequences.

The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.

The invention discloses primer sequences and a quantitative determination kit used for simultaneously detecting human CMV and BK virus DNA. The invention discloses primers, fluorescent probes, and a real-time quantitative polymerase chain reaction (real-time PCR) kit used for simultaneously carrying out quantitative determinations on deoxyribonucleic acid (DNA) segments of cytomegalovirus (CMV) and BK virus (BKV). The kit comprises reagent A, B, C, D, E, and G. The reagent A is composed of a mixed set of primers and probes, wherein the primers and probes are targeted at consensus sequences ofCMV DNA and BKV DNA. The reagent B is a buffer solution containing dNTP. The reagent C is Tag DNA polymerase. The reagent D is composed of standard samples with different concentrations. The reagent E and G are respectively positive and negative controls. With the whole set of kit provided by the invention, quantitative determinations can be simultaneously carried out on DNA of CMV and BK virusesin clinical specimens of urine, blood or other body fluids.

The present application provides methods and compositions for treatment or reducing risk of dsDNA virus infection in post-hematopoietic cell transplant (HCT or HSCT) patients. This application also provides methods and composition for reducing the incidence of BK virus associated hematuria and / or renal impairment. The invention also relates to a method of lowering BK viral load in post-hematopoietic cell transplant (HCT or HSCT) patients with HDP-CDV (HDP-CDV) or compound of Formula II, or a pharmaceutically acceptable salt thereof, thereby delaying onset of or reducing risk of end organ disease in these patients.

The invention discloses a JC virus detection method. The JC virus detection method comprises the following steps: extracting JCV DNA from human urine sample by utilizing a paramagnetic particle method, thereby obtaining a sample to be detected; performing PCR amplification reaction; utilizing a fluorescent quantitative PCR meter to detect reaction results, and when collecting fluorescent signals, setting fluorescein corresponding to a fluorescent group at Taqman fluorescent probe JCV-FP 5' end to collect the fluorescent signals at 60 DEG. The invention further provides a kit for detecting the JC virus. The detection method is high in sensitivity, can detect to 500 copies / mL at the lowest extent; and meanwhile, the specificity of the detection method is good, and according to the detection method, and no cross reaction with other virus occurs, such as BK virus (BKV), hepatitis C virus (HCV), human cytomegalovirus (HCMV), and hepatitis B virus (HBV).

The present invention is a method of using the BK enhances in tandem with a eukaryotic promoter to promote transcription of DNA that encodes a useful substance. The method of the present invention requires the presence of the E1A gene produce for maximum expression of the useful substance. The present invention also comprises a number of useful expression vectors that comprise the BK enhancer in tandem with the adenovirus 2 late promoter positioned to drive expression of a variety of proteins, such as protein C, chloramphenicol acetyltransferase, and tissue plasminogen activator. The present invention further comprises a method for increasing the activity of the BK enhancer involving placement of the BK enhancer immediately upstream of the eukaryotic promoter used in tandem with the BK enhancer to drive expression of a useful substance. Furthermore, the present invention also comprises a method for coamplification of genes in primate cells. Additionally, the invention further comprises the recombinant human protein C molecule produced in 293 cells which comprises novel glycosylation patterns.

The present invention is a method of using the BK enhancer in tandem with a eukaryotic promoter to promote transcription of DNA that encodes a useful substance. The method of the present invention requires the presence of the E1A gene product for maximum expression of the useful substance. The present invention also comprises a number of useful expression vectors that comprise the BK enhancer in tandem with the adenovirus 2 late promoter positioned to drive expression of a variety of proteins, such as protein C, chloramphenicol acetyltransferase, and tissue plasminogen activator. The present invention further comprises a method for increasing the activity of the BK enhancer involving placement of the BK enhancer immediately upstream of the eukaryotic promoter used in tandem with the BK enhancer to drive expression of a useful substance. Furthermore, the present invention also comprises a method for coamplification of genes in primate cells. Additionally, the invention further comprises the recombinant human protein C molecule produced in 293 cells which comprises novel glycosylation patterns.

The invention discloses a detection primer group for detecting organ transplantation postoperative infection. The detection primer group comprises a multiplex-PCR (Polymerase Chain Reaction) primer group and a general primer group for CMV (Cytomegalovirus), EBV (Epstein-Barr virus), BK (BK virus), HBV (Hepatitis B Virus) and B19 (Human Parvovirus19). The detection primer group is capable of detecting five viruses in the same reaction system under the same amplification condition, virus detection coverage is wide, detection efficiency is high, and specificity is high. Meanwhile, the detection primer group is capable of enabling PCR amplification products to be directly applied to high-throughput sequencing, and detection throughput and detection sensitivity are improved. The invention further discloses a detection reagent comprising the detection primer group. The invention further discloses a sequencing library for detecting organ transplantation postoperative infection and a construction method of the sequencing library. According to the construction method of the sequencing library, construction steps of the conventional library are effectively simplified, and construction efficiency is improved.

The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.

Provided herein are methods of rapidly expanding BKV-specific T cells using a peptide mixture and cytokines. Further provided herein are methods of treating polyomavirus-associated diseases by administering the BKV-specific T cells.

Methods for the rapid detection of the presence or absence of BK virus in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting BK virus and kits are provided that are designed for the detection of BK virus.

The invention discloses primers, probe and kit used for detecting BK viruses (BKVs), belonging to the technical field of biology. The primers and probe comprise a forward primer, a reverse primer and a probe, which are used for detecting BKVs. The kit comprises the primers and the probe. The primers, the probe and the kit have the characteristic of high sensitivity, the detection speed is high and the whole detection process only takes 2-3 hours.

The invention relates to the field of medical molecular biology detection, in particular to a primer and a probe capable of simultaneously detecting a BK virus and a JC virus, and a purpose. The invention provides a primer group capable of simultaneously detecting the BK virus and the JC virus. The primer group is designed on the basis of nucleotide sequences disclosed by SEQ ID NO.1 and SEQ ID NO.2, the above target sequence can meet a primer design requirement in a range of 100-200bp, meanwhile, the primer designed on the basis of the target sequence can effectively authenticate the BK virusand also can accurately authenticate the JC virus, and difficulty to design a fragment suitable for the primer is high.

Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and / or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and / or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.

Provided herein are methods of rapidly expanding BKV-specific T cells using a peptide mixture and cytokines. Further provided herein are methods of treating polyomavirus-associated diseases by administering the BKV-specific T cells.

The invention discloses a kit and a method for detecting a BK virus in urine. The kit comprises a 2*Taq Mix, a BK virus amplification primer and ddH2O, wherein the BK virus amplification primer is asfollows: F: GGGCAGCGCACGATGTTTT; R: AGCTGCCCCTGGACACTCT. The detection method comprises the following steps in sequence: 1: obtaining a sample to be detected; 2, preparing a PCR reaction solution; 3,carrying out PCR amplification; 4, recovering a target strip; 5, purifying the DNA recovered from the sample, and then connecting a vector for sequencing; and 6, comparing the measured sequence with the sequence of the BK virus, indicating that the BK virus exists in the sample if the sequences are consistent, and indicating that the BK virus does not exist in the sample if the sequences are inconsistent or no strip with the same size as the positive control exists in a sample tube. The kit and the method for detecting the BK virus in urine can rapidly detect whether the urine contains the BKvirus or not, are high in accuracy and short in period, and adopt a specific BK primer, so that the detection specificity is high.

The invention discloses primer sequences and a quantitative determination kit used for simultaneously detecting human CMV and BK virus DNA. The invention discloses primers, fluorescent probes, and a real-time quantitative polymerase chain reaction (real-time PCR) kit used for simultaneously carrying out quantitative determinations on deoxyribonucleic acid (DNA) segments of cytomegalovirus (CMV) and BK virus (BKV). The kit comprises reagent A, B, C, D, E, and G. The reagent A is composed of a mixed set of primers and probes, wherein the primers and probes are targeted at consensus sequences ofCMV DNA and BKV DNA. The reagent B is a buffer solution containing dNTP. The reagent C is Tag DNA polymerase. The reagent D is composed of standard samples with different concentrations. The reagent E and G are respectively positive and negative controls. With the whole set of kit provided by the invention, quantitative determinations can be simultaneously carried out on DNA of CMV and BK virusesin clinical specimens of urine, blood or other body fluids.

Methods for the rapid detection of the presence or absence of BK virus in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting BK virus and kits are provided that are designed for the detection of BK virus.

The invention relates to a detection method of a virus and a kit and particularly relates to a detection method of a BK virus and a kit thereof. The detection method comprises the following steps of: firstly, designing specific primers BKV-F and BKV-R and a Taqman fluorescence probe BKV-P aiming at a BK virus gene group; marking a fluorophore on a 5' end of the Taqman fluorescence probe BKV-P andmarking a quencher at any position the Taqman fluorescence probe BKV-P except the 5' end; then treating a sample to be detected and carrying out PCR (Polymerase Chain Reaction); and finally, detecting a reaction result by using a fluorescent quantitation PCR instrument. The detection method disclosed by the invention has the advantages that the qualitative and quantitative detection can be realized, and high sensibility, good specificity, rapid reaction and low cost also can be realized. The invention further relates to a detection kit of the BK virus and an application of the detection method.

The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.

A nucleic acid probe set is disclosed. The nucleic acid probe set comprises a detection probe and a capture probe, and the detection probe and the capture probe both include a nucleotide sequence that is extracted from a conserved region of a genome sequence belong to a BK virus. A nucleic acid lateral flow immunoassay for using in detection of BK virus is also disclosed. The nucleic acid lateral flow immunoassay comprises: the forgoing nucleic acid probe set, a test strip, and a streptavidin (SA) solution. Experimental data have proved that, the nucleic acid lateral flow immunoassay can be adopted for conducting a BK virus detection on a sample that is collected from environmental water, sewage water, drinking water, urine, or serum.

Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and / or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and / or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.

The invention provides a method for detecting a BK virus based on a loop-mediated isothermal amplification (LAMP) technology, a primer group for the method and a corresponding kit. The BK virus can be subjected to specific loop-mediated isothermal amplification by utilizing the primer group. The method disclosed by the invention is good in specificity, high in sensitivity, good in repeatability, simple to operate, convenient and rapid, can be well applied to identification of the BK virus, and is suitable for clinical and laboratory detection.

The invention relates to a reagent for detecting a BK virus and a JC virus and application, and belongs to the technical field of biological medicines. A section of JCV fragment notch region exists in highly conserved regions of BKV and JCV. A primer probe system for simultaneously targeting BKV and JCV is designed at a suitable position beyond the notch region, and a reverse primer is only designed in the notch region to specifically target BKV or JCV. The reagent is used for preliminary screening, BKV and JCV are targeted at the same time, and resource saving is facilitated; and BKV or JCV can be accurately judged, and the reagent is suitable for clinical popularization. According to the invention, BKV and JCV activation can be prevented, the treatment effect of related diseases can be evaluated in time, the defects and deficiencies of the existing detection system are made up, and the detection result is more reliable. BKV and JCV are taken into consideration, primary screening can be carried out by targeting BKV and JCV at the same time, BKV or JCV can be accurately judged, and timely immunosuppression adjustment is facilitated.

Novel thiazole- and isoquinoline- containing compounds are presented that are useful for treating and / or preventing broad-spectrum viral infections. Methods of treating and / or preventing broad-specturm viral infections are also presented. These compounds have shown inhibitio of HCMV, influenza viruses, Zika virus, BK Virus and RSV replication in cell-based assays.